208 related articles for article (PubMed ID: 35623961)
21. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
22. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
Schumann K; Mauch C; Klespe KC; Loquai C; Nikfarjam U; Schlaak M; Akçetin L; Kölblinger P; Hoellwerth M; Meissner M; Mengi G; Braun AD; Mengoni M; Dummer R; Mangana J; Sindrilaru MA; Radmann D; Hafner C; Freund J; Rappersberger K; Weihsengruber F; Meiss F; Reinhardt L; Meier F; Rainer B; Richtig E; Ressler JM; Höller C; Eigentler T; Amaral T; Peitsch WK; Hillen U; Harth W; Ziller F; Schatton K; Gambichler T; Susok L; Maul LV; Läubli H; Debus D; Weishaupt C; Börger S; Sievers K; Haferkamp S; Zenderowski V; Nguyen VA; Wanner M; Gutzmer R; Terheyden P; Kähler K; Emmert S; Thiem A; Sachse M; Gercken-Riedel S; Kaune KM; Thoms KM; Heinzerling L; Heppt MV; Tratzmiller S; Hoetzenecker W; Öllinger A; Steiner A; Peinhaupt T; Podda M; Schmid S; Wollina U; Biedermann T; Posch C
J Eur Acad Dermatol Venereol; 2023 May; 37(5):894-906. PubMed ID: 36433688
[TBL] [Abstract][Full Text] [Related]
23. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
26. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
27. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
[TBL] [Abstract][Full Text] [Related]
29. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
30. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
31. The extent of surgery for stage III melanoma: how much is appropriate?
Franke V; van Akkooi ACJ
Lancet Oncol; 2019 Mar; 20(3):e167-e174. PubMed ID: 30842060
[TBL] [Abstract][Full Text] [Related]
32. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N; Tsutsumida A; Takahashi A; Namikawa K; Yoshikawa S; Fujiwara Y; Kondo S; Mukaiyama A; Zhang F; Kiyohara Y
J Dermatol; 2018 Apr; 45(4):397-407. PubMed ID: 29399853
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
36. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
[TBL] [Abstract][Full Text] [Related]
37. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
38. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
40. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
